Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
暂无分享,去创建一个
Peter A Kaufman | James N Ingle | Edith A Perez | E. Perez | S. Martino | J. Ingle | N. Davidson | V. Suman | P. Roche | R. Jenkins | P. Kaufman | Patrick C Roche | Robert B Jenkins | Silvana Martino | Nancy E Davidson | F. Addo | B. Murphy | Vera J Suman | Ferdinand K Addo | Bronagh Murphy
[1] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Clark. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? , 1998, Journal of the National Cancer Institute.
[3] Greg Yothers,et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.
[4] James N Ingle,et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. , 2002, Mayo Clinic proceedings.
[5] S. Bull,et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.
[8] S Toikkanen,et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Martino,et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B Fisher,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.
[12] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.